Eric Segal1, Michael Martens2, Hai-Lin Wang3, Ruta Brazauskas2, Daniel Weisdorf4, Brenda M Sandmaier5, H Jean Khoury6, Marcos de Lima7, Wael Saber3. 1. Medical College of Wisconsin Affiliated Hospitals, Milwaukee, Wisconsin. 2. Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota. 5. Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. 6. Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia. 7. University Hospitals Case Medical Center, Cleveland, Ohio.
Abstract
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-matched related donors (RDs) and allogeneic HCT using HLA-matched unrelated donors (URDs) produce similar outcomes for patients with acute myelogenous leukemia, whereas the donor source has been reported to be a predictor of outcomes in myelodysplastic syndrome. METHODS: Post-HCT outcomes for 1458 acute lymphoblastic leukemia patients from 2000 to 2011 were analyzed, and RD and URD transplants were compared. RESULTS: The median age was 37 years (range, 18-69 years). In the multivariate analysis, HLA 8/8 allele-matched URD recipients had similar transplant-related mortality (TRM) and all-cause mortality in comparison with RD recipients (hazard ratios [HRs], 1.16 [95% confidence interval (CI), 0.91-1.48] and 1.01 [95% CI, 0.85-1.19], respectively); 7/8 URD recipients had a greater risk of TRM and all-cause mortality in comparison with RD recipients (HRs, 1.92 [95% CI, 1.47-2.52] and 1.29 [95% CI, 1.05-1.58], respectively). The risk of TRM and all-cause mortality was also greater for 7/8 URD recipients versus 8/8 URD recipients. Compared with RD recipients, both 8/8 and 7/8 URD recipients had a lower risk of relapse (HRs, 0.77 [95% CI, 0.62-0.97] and 0.75 [95% CI, 0.56-1.00], respectively). Both 8/8 and 7/8 URD recipients had a greater risk of acute graft-versus-host disease (GVHD; HRs, 2.18 [95% CI, 1.76-2.70] and 2.65 [95% CI, 2.06-3.42], respectively) and chronic GVHD (HRs, 1.28 [95% CI, 1.06-1.55] and 1.46 [95% CI, 1.14-1.88], respectively) in comparison with RD recipients. CONCLUSIONS: In the absence of RD transplantation, 8/8 URD transplantation is a viable alternative with similar survival outcomes, whereas 7/8 URD transplantation is associated with poorer overall survival. Cancer 2017;123:3346-55.
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-matched related donors (RDs) and allogeneic HCT using HLA-matched unrelated donors (URDs) produce similar outcomes for patients with acute myelogenous leukemia, whereas the donor source has been reported to be a predictor of outcomes in myelodysplastic syndrome. METHODS: Post-HCT outcomes for 1458 acute lymphoblastic leukemiapatients from 2000 to 2011 were analyzed, and RD and URD transplants were compared. RESULTS: The median age was 37 years (range, 18-69 years). In the multivariate analysis, HLA 8/8 allele-matched URD recipients had similar transplant-related mortality (TRM) and all-cause mortality in comparison with RD recipients (hazard ratios [HRs], 1.16 [95% confidence interval (CI), 0.91-1.48] and 1.01 [95% CI, 0.85-1.19], respectively); 7/8 URD recipients had a greater risk of TRM and all-cause mortality in comparison with RD recipients (HRs, 1.92 [95% CI, 1.47-2.52] and 1.29 [95% CI, 1.05-1.58], respectively). The risk of TRM and all-cause mortality was also greater for 7/8 URD recipients versus 8/8 URD recipients. Compared with RD recipients, both 8/8 and 7/8 URD recipients had a lower risk of relapse (HRs, 0.77 [95% CI, 0.62-0.97] and 0.75 [95% CI, 0.56-1.00], respectively). Both 8/8 and 7/8 URD recipients had a greater risk of acute graft-versus-host disease (GVHD; HRs, 2.18 [95% CI, 1.76-2.70] and 2.65 [95% CI, 2.06-3.42], respectively) and chronic GVHD (HRs, 1.28 [95% CI, 1.06-1.55] and 1.46 [95% CI, 1.14-1.88], respectively) in comparison with RD recipients. CONCLUSIONS: In the absence of RD transplantation, 8/8 URD transplantation is a viable alternative with similar survival outcomes, whereas 7/8 URD transplantation is associated with poorer overall survival. Cancer 2017;123:3346-55.
Authors: W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum Journal: N Engl J Med Date: 2001-01-18 Impact factor: 91.245
Authors: Theresa Hahn; Philip L McCarthy; Anna Hassebroek; Christopher Bredeson; James L Gajewski; Gregory A Hale; Luis M Isola; Hillard M Lazarus; Stephanie J Lee; Charles F Lemaistre; Fausto Loberiza; Richard T Maziarz; J Douglas Rizzo; Steven Joffe; Susan Parsons; Navneet S Majhail Journal: J Clin Oncol Date: 2013-05-28 Impact factor: 44.544
Authors: Priya Kumar; Todd E Defor; Claudio Brunstein; Juliet N Barker; John E Wagner; Daniel J Weisdorf; Linda J Burns Journal: Biol Blood Marrow Transplant Date: 2008-12 Impact factor: 5.742
Authors: Michael B Tomblyn; Mukta Arora; K Scott Baker; Bruce R Blazar; Claudio G Brunstein; Linda J Burns; Todd E DeFor; Kathryn E Dusenbery; Dan S Kaufman; John H Kersey; Margaret L MacMillan; Philip B McGlave; Jeffrey S Miller; Paul J Orchard; Arne Slungaard; Marcie R Tomblyn; Gregory M Vercellotti; Michael R Verneris; John E Wagner; Daniel J Weisdorf Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: Wael Saber; Corey S Cutler; Ryotaro Nakamura; Mei-Jie Zhang; Ehab Atallah; J Douglas Rizzo; Richard T Maziarz; Jorge Cortes; Matt E Kalaycio; Mary M Horowitz Journal: Blood Date: 2013-07-11 Impact factor: 22.113
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: Mazyar Shadman; Jordan Gauthier; Kevin A Hay; Jenna M Voutsinas; Filippo Milano; Ang Li; Alexandre V Hirayama; Mohamed L Sorror; Sindhu Cherian; Xueyan Chen; Ryan D Cassaday; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; David G Maloney; Cameron J Turtle Journal: Blood Adv Date: 2019-10-22
Authors: Stefan O Ciurea; Maria Cecilia Borges Bittencourt; Denái R Milton; Kai Cao; Piyanuch Kongtim; Gabriela Rondon; Julianne Chen; Marina Konopleva; Jorge M Ramos Perez; Mohammed F El Shazly; Majdi Aljadayeh; Michele Alvarez; Jin Im; Gheath Al-Atrash; Rohtesh Mehta; Uday Popat; Qaiser Bashir; Betul Oran; Chitra M Hosing; Issa F Khouri; Partow Kebriaei; Richard E Champlin Journal: Blood Adv Date: 2018-09-11
Authors: Matthew J Wieduwilt; Leland Metheny; Mei-Jie Zhang; Hai-Lin Wang; Noel Estrada-Merly; David I Marks; A Samer Al-Homsi; Lori Muffly; Nelson Chao; David Rizzieri; Robert Peter Gale; Shahinaz M Gadalla; Mitchell Cairo; Alberto Mussetti; Steven Gore; Vijaya Raj Bhatt; Sagar S Patel; Fotios V Michelis; Yoshihiro Inamoto; Sherif M Badawy; Edward Copelan; Neil Palmisiano; Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Siddhartha Ganguly; Christopher Bredeson; Miguel Angel Diaz Perez; Ryan Cassaday; Bipin N Savani; Karen Ballen; Rodrigo Martino; Baldeep Wirk; Ulrike Bacher; Mahmoud Aljurf; Asad Bashey; Hemant S Murthy; Jean A Yared; Ibrahim Aldoss; Nosha Farhadfar; Hongtao Liu; Hisham Abdel-Azim; Edmund K Waller; Melhem Solh; Matthew D Seftel; Marjolein van der Poel; Michael R Grunwald; Jane L Liesveld; Rammurti T Kamble; Joseph McGuirk; Reinhold Munker; Jean-Yves Cahn; Jong Wook Lee; César O Freytes; Maxwell M Krem; Lena E Winestone; Usama Gergis; Sunita Nathan; Richard F Olsson; Leo F Verdonck; Akshay Sharma; Olle Ringdén; Brian D Friend; Jan Cerny; Hannah Choe; Saurabh Chhabra; Taiga Nishihori; Sachiko Seo; Biju George; Lee Ann Baxter-Lowe; Gerhard C Hildebrandt; Marcos de Lima; Mark Litzow; Partow Kebriaei; Christopher S Hourigan; Muhammad Bilal Abid; Daniel J Weisdorf; Wael Saber Journal: Blood Adv Date: 2022-01-11